The original study by Tsai et al.41 reported that, at 100 nM, vemurafenib suppressed phosphorylation of ERK in a melanoma cell line harboring the B-Raf V600E mutation, but also showed that at concentrations over 1 μM it suppressed phosphorylation of ERK in another melanoma cell line with wild-type B-Raf. Here, BRAF is linked to melanoma.